You just read:

Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

News provided by

Soligenix, Inc.

Aug 28, 2019, 07:00 ET